Regulatory Blogs

ArisGlobal, part of the more cautious and highly regulated life science go “all-in on AWS” by moving the entire cloud infrastructure to the AWS platform. This move benefits both ArisGlobal and to our customers.

Examining the challenges involved, benefits to be gained and requirements of unified regulatory and clinical business processes, as well as recommendations for taking the next steps forward.

“Driving insights to action” was this year’s DIA Annual conference theme, and represented a perfect fit for where ArisGlobal…

As evident from our second polling question, ”How far along the road would you say you are for a ‘new’ technological revolution,” the journey to capitalize on the next industrial revolution is just beginning for most participants

As evident from our second polling question, ”How far along the road would you say you are for a ‘new’ technological revolution,” the journey to capitalize on the next industrial revolution is just beginning for most participants

Automation technologies are having a major impact on performance and productivity across industries. In regulatory, these technologies also have the potential to reshape many activities across regulatory, leading to significant productivity gains. While there’s a lot of talk about how automation technologies will create new roles with exciting opportunities, the most powerful impact will be on the data quality and the efficiency with which manual tasks will be accomplished.

Rising Expectations from Regulatory Affairs Executives As we all know from experience, not all cloud solutions are the same and…

This is the last in the ArisGlobal three-part blog series on Regulatory Affairs transformation. Digitization is sweeping the life sciences industry, disrupting traditional working practices and opening doors to better ways of collaborating, tracking and sharing documents and data, and gaining clear oversight into the product supply chain.

The life sciences industry is confronting a wave of transformational change, brought about by multiple factors, including the growth of new clinical trial markets, a rapid rise in drug development innovation, reimbursement challenges, heightened regulatory requirements and a demand for evidence-based medicine, among many others. These drivers and the resultant changes are having a profound effect on regulatory affairs.

Regulatory affairs departments are accustomed – and even open — to change and adapting their technology and processes in response…